Histogen: Unterschied zwischen den Versionen
(Die Seite wurde neu angelegt: „{{NYT en}} '''Histogen''' is a biotech company from San Diego founded by Gail K. Naughton. They are researching an injectable treatment to promote hair gro…“) |
(kein Unterschied)
|
Version vom 22. November 2019, 22:22 Uhr
(Dieser Artikel wurde noch nicht aus dem Englischen übersetzt oder enthält noch englische Textpassagen. Bitte beziehe dich vorerst auf die Informationen im englischen Artikel. Klicke dazu in der IntactiWiki-Navigation im Abschnitt "In anderen Sprachen" auf "English".)
Histogen is a biotech company from San Diego founded by Gail K. Naughton. They are researching an injectable treatment to promote hair growth called Hair Stimulating Complex, or HSC. This treatment is manufactured using harvested infant foreskins removed by circumcision.[1]
Hair Stimulating Complex
HSC contains proteins, chemicals called growth factors and other substances produced by skin cells called fibroblasts. The substances are produced when the cells are grown in a low-oxygen environment mimicking an embryonic environment.
The fibroblasts are taken from neonatal foreskins, the byproduct of circumcisions. These are the same cells used by the defunct San Diego company Advanced Tissue Sciences, which produced a living skin product called Dermagraft It's not a coincidence: Naughton was president and COO of the company. Dermagraft is now being made in San Diego by a subsidiary of Shire, a medical company based in Dublin, Ireland.[1]
The United States Patent & Trademark Office issued patent 8,257,947, entitled "Extracellular Matrix Compositions Produced Under Hypoxic Culture Conditions" to Histogen. The patent, which is the Company's first patent issued in the United States, covers Histogen's method of growing cells under low oxygen and suspension conditions, and the process through which the naturally-secreted protein compositions are produced.[1]
On October 2012 Histogen announced preliminary data from a combined Phase 1/2 clinical trial. In this trial, patients aged 40-59 showed a mean increase of 39 percent in so-called terminal hair, as opposed to fine hair called vellus hair. Hair regrowth took place across all regions of the scalp.[1]
Gail K. Naughton
Naughton was president and COO of Advanced Tissue Sciences, which produced a living skin product call Dermagraft used to help healing of diabetic foot ulcers. Dermagraft is now being made in San Diego by a subsidiary of Shire, a medical company based in Dublin, Ireland.
Naughton founded Histogen in 2007, when she was dean of San Diego State University's College of Business Administration. Naughton, who had been dean since 2002, left in 2010 to focus on Histogen. [2]
Einzelnachweise
- ↑ a b c d
(19. Oktober 2012). Hair growth treatment works, says San Diego's Histogen
, UT San Diego. Abgerufen 16. November 2012. - ↑ (5. September 2012).
U.S. Patent issued for Histogen's Novel Cell Growth Process
, Histogen. Abgerufen 16. November 2012.
